These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 22505700

  • 1. Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.
    Yu X, Wang L, Xu P, Lu W, Lan G, Ping L, Wang X, Tian J, Liu J.
    J Rheumatol; 2012 Jun; 39(6):1171-8. PubMed ID: 22505700
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 6. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A.
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [Abstract] [Full Text] [Related]

  • 7. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
    O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD.
    Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
    [Abstract] [Full Text] [Related]

  • 8. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
    Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M, FIN-RACo Trial Group.
    Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD, Lester S, Proudman SM, Cleland LG, Whittle SL, Rischmueller M, Hill CL.
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [Abstract] [Full Text] [Related]

  • 14. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T, Amara I, Koch GG.
    Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G.
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, Cohen S, Felson D.
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [Abstract] [Full Text] [Related]

  • 20. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.